Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
The company expects top-line data from its OCU400 retinitis pigmentosa program in the first quarter of 2027, followed by a rolling BLA submission. Top-line data from OCU410ST in Stargardt disease is projected for the second quarter of 2027, while Ocugen is targeting a late-2028 BLA submission for OCU410 in geographic atrophy.
Gene Therapy Strategy and Manufacturing Readiness
“Our therapies are potentially one-time treatments for life,” Musunuri said, describing the approach as potentially applicable across broad patient populations rather than small groups defined by a single mutation.
For OCU400, Musunuri said the company has completed process performance qualification runs and process validation activities. It also introduced two commercial-scale lots into its Phase III program. The nonclinical and chemistry, manufacturing and controls modules are ready, he said, leaving clinical data as the primary remaining component for a filing.
Following OCU400 data, Ocugen plans to meet with the U.S. Food and Drug Administration in a pre-BLA meeting and align on its submission plan. Musunuri also said the European Medicines Agency waived additional clinical-trial requirements for OCU400 and OCU410ST, allowing Ocugen to use its U.S. clinical data in European marketing authorization filings.
Stargardt Trial Continues Following DMC Review
Musunuri addressed a Sept. 3 update on a pre-specified independent data monitoring committee review of 26 OCU410ST-treated subjects. He said the review was blinded and found that lesion-size differences did not favor the treatment group in the partial data reviewed.
According to Musunuri, the committee’s assessment of the full data set indicated the effect was expected to be neutral, and its ultimate recommendation was to continue the study. He attributed some uncertainty to the small data set and variability in lesion size among participants.
“The bottom line is the study is continuing,” Musunuri said, adding that investors should wait for top-line data from the 12-month study. He said the company has added resources to the program, including a retinal specialist serving as chief medical officer.
Ocugen expects the pivotal Phase II/III GARDian3 study of OCU410ST to produce top-line results in the second quarter of 2027, according to the operator’s introduction.
Geographic Atrophy Program Moves Into Phase III
Ocugen dosed the first patient in its Phase III ArMaDa3 trial of OCU410 for geographic atrophy on Sept. 1, following an end-of-Phase II meeting with the FDA in July. Musunuri said the FDA agreed that lesion reduction would serve as the primary endpoint for the one-year study.
He said Phase II data showed a 31% lesion reduction in the studied population and that approximately 20% of patients receiving the selected dose had lesions that stabilized. The Phase III trial is designed to enroll 237 patients, which Musunuri said provides 95% power for the primary endpoint. Secondary endpoints include ellipsoid zone measurements and low-luminance visual acuity.
The company expects recruitment to take roughly nine to 12 months and plans to add European sites to existing U.S. and Canadian participation. Musunuri said Ocugen is targeting top-line data in the second half of 2028 and a BLA filing later that year.
OCU410 received Regenerative Medicine Advanced Therapy designation from the FDA. Musunuri said the designation could provide a potential priority-review pathway, with a six-month review timeline rather than the 10 to 12 months he cited for regular therapies.
Commercialization and Capital Plans
Musunuri said Ocugen is conducting lower-cost commercialization planning ahead of potential approvals, including discussions with payers and the Centers for Medicare & Medicaid Services, patient-registry work and development of treatment centers of excellence. The company’s therapies are administered through subretinal injection, a surgical procedure.
He said Ocugen expects to pursue strategic partnerships outside the United States while considering an independent U.S. launch. Musunuri cited more than 100,000 retinitis pigmentosa patients in the U.S. and an estimated 1 million to 2 million U.S. geographic atrophy patients.
Ocugen ended the second quarter with $130 million in cash and had retired some debt, according to the operator. Musunuri said the company aims to extend its cash runway into 2028 and will seek to limit shareholder dilution through potential ex-U.S. partnerships, non-dilutive funding and financing alternatives such as royalty-based arrangements, while retaining the option to raise equity if needed.
About Ocugen (NASDAQ:OCGN)
Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.
Ocugen’s leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively.
